SRR650195
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.650
- E2F_TARGETS+0.630
- G2M_CHECKPOINT+0.610
- MYC_TARGETS_V1+0.560
- TGF_BETA_SIGNALING+0.520
- INTERFERON_GAMMA_RESPONSE+0.500
- MITOTIC_SPINDLE+0.490
- MTORC1_SIGNALING+0.470
- PI3K_AKT_MTOR_SIGNALING+0.410
- MYC_TARGETS_V2+0.400
Top 10 suppressed
- BILE_ACID_METABOLISM-0.330
- XENOBIOTIC_METABOLISM-0.240
- FATTY_ACID_METABOLISM-0.220
- ADIPOGENESIS-0.210
- MYOGENESIS-0.200
- PEROXISOME-0.170
- PANCREAS_BETA_CELLS-0.160
- OXIDATIVE_PHOSPHORYLATION-0.120
- COAGULATION-0.060
- KRAS_SIGNALING_UP-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A3N5-01A-11R-A21D-07 | — | — | 0.930 |
| 2 | TCGA-GC-A3RC-01A-11R-A22U-07 | — | — | 0.930 |
| 3 | TCGA-BT-A3PJ-01A-21R-A220-07 | — | — | 0.893 |
| 4 | TCGA-CV-7434-01A-11R-2132-07 | — | — | 0.889 |
| 5 | TCGA-G2-A2EJ-01A-11R-A180-07 | — | — | 0.889 |
| 6 | MNG1210 | — | — | 0.878 |
| 7 | TCGA-DK-AA6R-01A-11R-A42T-07 | — | — | 0.870 |
| 8 | MDT-AP-3375 | Med | Medulloblastoma | 0.864 |
| 9 | TCGA-FD-A3N6-01A-11R-A21D-07 | — | — | 0.855 |
| 10 | TCGA-CF-A1HS-01A-11R-A13Y-07 | — | — | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.650 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.610 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.490 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.360 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |